Taiwan-based Caliway Biopharmaceuticals (TWSE: 6919) has reported positive final results from its placebo-controlled Phase IIb trial of CBL-514 in Dercum's Disease, a rare disorder characterized by chronically painful lipomas for which no approved pharmacological treatment exists.
The CBL-0202DD trial met its primary efficacy endpoint. In the full analysis set (FAS) population, patients receiving CBL-514 achieved a mean pain-score reduction of 3.1 points at Week 20 versus 1.9 points with placebo (p=0.005). In the per-protocol (PP) population, the same 3.1-point reduction compared with 1.4 points for placebo (p=0.0002). Secondary endpoints at Weeks 16 and 24 also reached statistical significance in both populations, with the treatment effect increasing over time — patients receiving CBL-514 achieved mean pain reductions of 4.1 points by Week 24. An exploratory analysis reported that approximately 90% of CBL-514-treated patients in the FAS population achieved a clinically meaningful pain reduction of at least 3 points in more than half of their treated lipomas. No drug-related serious adverse events were reported; the most common treatment-emergent adverse events were mild-to-moderate local injection-site reactions.
CBL-514 is a small-molecule injectable that selectively induces adipocyte apoptosis, directly reducing the lipoma tissue responsible for pain in Dercum's Disease. This mechanism differs fundamentally from current off-label management — analgesics, IV lidocaine, and surgical excision — none of which hold regulatory approval for the indication and none of which address the underlying lipoma burden.
The drug holds FDA Orphan Drug Designation and Fast Track Designation for Dercum's Disease, as well as EMA Orphan Drug Designation. Caliway said it plans to collaborate with clinical experts to evaluate a development strategy for lipedema, a related adipose tissue disorder the company said affects approximately 10% of women globally — a market size figure Caliway attributed to epidemiological and market research data, not independently verified. The CBL-0202DD results also follow positive Phase II data from the earlier uncontrolled CBL-0201DD study, which demonstrated lipoma dimension reductions and a 4.7-point pain improvement.